Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.74 |
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | SCN1A | P35498 | 2/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midaglizole SCHEMBL30029057 | 1.00 | NISCH (0.74) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL752697 | 0.99 | NISCH (0.72) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL9403180 | 0.99 | NISCH (0.72) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7548321 | 0.92 | NISCH (0.66) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| Midaglizole SCHEMBL4783531 | 0.90 | NISCH (0.60) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7547511 | 0.87 | NISCH (0.57) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7555329 | 0.87 | NISCH (0.57) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7548764 | 0.87 | NISCH (0.56) | NISCHMAOAMAOBSLC6A2SLC6A4 | |
| SCHEMBL7547171 | 0.86 | NISCH (1.00) | NISCHMAOAMAOBTSHRLMNA | |
| SCHEMBL7553919 | 0.85 | NISCH (0.54) | NISCHMAOAMAOBSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1984 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20250339448-A1 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | REMEDY PHARMACEUTICALS, INC. (US) | 2025-11-06 | — | — | US | claimed |
| US-20250325564-A1 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | REMEDY PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| US-20250325504-A1 | METHODS OF TREATING ISCHEMIC STROKE AT RISK FOR CEREBRAL OR CEREBELLAR EDEMA | REMEDY PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-12337006-B1 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-20250161330-A1 | METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS | REMEDY PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | US | claimed |
| US-12251389-B1 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | REMEDY PHARMACEUTICALS, INC. (US) | 2025-03-18 | — | — | US | claimed |
| EP-4299127-A2 | METHODS OF MEDICAL TREATMENT WITH SUR1-TRPM4 CHANNEL INHIBITORS | Remedy Pharmaceuticals, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20030216294-A1 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor | PFIZER INC. | 2003-11-20 | — | — | US | claimed |
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PFIZER INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003079987-A2 | A NON-SELECTIVE CATION CHANNEL IN NEURAL CELLS AND METHODS FOR TREATING BRAIN SWELLING | UNIVERSITY OF MARYLAND BALTIMORE (US) | 2003-10-02 | — | — | WO | claimed |
| US-6576653-B2 | For therapy of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis | PFIZER INC. | 2003-06-10 | — | — | US | claimed |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | DU BOIS DAISY JOE (US) | 2002-12-05 | — | — | US | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| US-20020013268-A1 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor | FRYBURG DAVID A (US) | 2002-01-31 | — | — | US | claimed |
| EP-1145717-A2 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| US-4138491-A | 2-/2-PHENYL-2-/2-PYRIDYL//ETHYLIMIDAZOLINE | DAIICHI SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195361-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, GYS1, PYGM | NISCH 3359/4885MAOA 2613/4885MAOB 2484/4885 |
| US-20260115210-A1 | METHOD FOR TREATING SUBJECTS SUFFERING FROM CENTRAL NERVOUS SYSTEM CONTUSIONS | AQP4, TRPM4, MMP24 | NISCH 2876/4885MAOA 1330/4885MAOB 1334/4885 |
| US-20020183369-A1 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | PYGL, PYGM, PYGB | NISCH 3425/4885MAOA 2334/4885MAOB 2166/4885 |
| US-12611416-B2 | Methods of treating ischemic stroke at risk for cerebral or cerebellar edema | TRPM4, ATP1A4, ATP1A3 | NISCH 3524/4885MAOA 2500/4885MAOB 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.